You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Outcomes and performance of risk scores and ProADM overall and in CAP and non-CAP-LRTI

From: Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: Derivation of a clinical algorithm

Parameters All patients (n = 1359) CAP (n = 925) Non-CAP (n = 379) P*
30 days outcomes     
Outpatient treatment, no (%) 142 (10%) 81 (9%) 61 (16%) <0.001
Length of hospital stay, median (IQR) 8 (4-12) 8 (5-12) 7 (3-11) <0.001
All cause mortality, no (%) 67 (4.9%) 50 (5.4%) 10 (2.6%) 0.03
ICU admission, no (%) 103 (7.6%) 83 (9.0%) 15 (4.0%) 0.002
Empyema, no (%) 31 (2.4%) 31 (3.3%) 0 <0.001
Any adverse events, no (%) 170 (12.2%) 134 (14.5%) 24 (6.3%) <0.001
CURB65 score     
CURB65 points, median (IQR) 2 (1-2) 2 (1-2) 1 (1-2) 0.002
CURB65 risk classes     0.001
CURB65 0-1, no (%) 659 (48.5%) 427 (46.2%) 211 (55.7%)  
CURB65 2, no (%) 434 (31.9%) 296 (32.0%) 114 (30.1%)  
CURB65 3-5, no (%) 266 (19.6%) 202 (21.8%) 54 (14.2%)  
AUC of CURB65 risk classes for adverse events (95%CI) 0.65 (0.61-0.69) 0.64 (0.59-0.65) 0.68 (0.57-0.78)  
AUC of CURB65 risk classes for mortality (95%CI) 0.73 (0.68-0.75) 0.72 (0.66-0.77) 0.74 (0.62-0.86)  
Initial proADM level (day 0)     
ProADM, median (IQR) (nmol/l) 1.1 (0.7-1.7) 1.2 (0.8-1.9) 0.9 (0.6-1.3) <0.001
ProADM categories     <0.001
ProADM <0.75 nmol/l, no (%) 353 (26.0%5) 194 (21.0%) 145 (38.3%)  
ProADM: 0.75 - 1.5 nmol/l, no (%) 588 (43.3%) 400 (43.2%) 166 (43.8%)  
ProADM >1.5 nmol/l, no (%) 418 (30.8%) 331 (35.8%) 68 (17.9%)  
AUC of proADM for adverse events (95%CI) 0.73 (0.69-0.78) 0.71 (0.67-0.78) 0.76 (0.66-0.85)  
AUC of proADM for mortality (95%CI) 0.79 (0.73-0.85) 0.76 (0.68-0.83) 0.88 (0.80-0.94)  
  1. AUC Area under the ROC curve; PSI Pneumonia Severity Index; CURB65 confusion, uremia, respiratory rate, blood pressure, age 65 years or greater; p value relates to difference between CAP and non-CAP-LRTI; of note, some patients had more than one adverse event, thus the numbers may not sum up to 100%. * Comparison CAP vs. Non-CAP